TokenPost·
United Therapeutics Q3 Revenue Rises 4% as Net Income Falls 24%
Diluted earnings per share declined 20% to $5.71, while research and development expense more than doubled to $279.2 million.
More news
- Crypto BriefingOil prices fall as Iran conflict resolution seems likely: WSJ
- TokenPostMeta Targets Up to 9 Billion Euros in Its First Euro Bond Offering
- TokenPostNatural Resource Partners Posts $1.95 Q3 GAAP EPS as Revenue Falls 10.2%
- TokenPostThe New York Times Company Adds 420,000 Net Digital-Only Subscribers in Q3 2026
- TokenPostZcash Rises 2.04% in One Hour to $1,315 on Binance Spot
- TokenPostBinance Plans AI Security Fund After $6.34 Billion Theft